Inclusion Criteria:  A prior confirmed positive test for COVID19 and lingering symptoms are required for inclusion.  As outlined on the CDC website, lingering symptoms include:  Tiredness or fatigue Difficulty thinking or concentrating (sometimes referred to as "brain fog") Headache Loss of smell or taste Dizziness on standing Fast-beating or pounding heart (also known as heart palpitations) Chest pain Difficulty breathing or shortness of breath Cough Joint or muscle pain Depression or anxiety Fever Symptoms that get worse after physical or mental activities  Exclusion Criteria:  Viral infections other than COVID-19. Clinically significant cardiac disease including uncontrolled congestive heart failure and unstable angina Pregnancy Females of childbearing potential age not on adequate contraception or lactating Subjects receiving systemic corticosteroid treatment within one month of Screening Visit Subjects Less than 18 years of age Hospitalization within last 6 months due to acute exacerbation of airway disease Subjects with a clinically significant abnormal chest x-ray within past 12 months Medication changes within one month of study entry Subjects who have participated in another investigation drug treatment study within the previous month. Subjects with a current history of alcohol or recreational drug abuse. Subjects who have taken dietary supplements containing pyruvate within 24 hours prior to the screening visit.